Observational study of localized angiosarcoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multi-institutional, prospective observational study focusing on patients with localized primary angiosarcoma (AS) across various sites. The study aims to standardize and better define the management of localized AS, particularly regarding the roles of radiation therapy and systemic treatment. By collecting clinical and pathological data from patients treated at reference centers in Italy, the study seeks to address existing gaps in knowledge about treatment approaches and prognostic factors for this rare cancer. The collaboration involves the Italian Sarcoma Group and the Italian Rare Cancer Network to enhance the quality of care for patients with rare tumors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* pathological diagnosis of AS;
* any site of origin;
* any age;
* primary, localized, resectable disease.

Exclusion Criteria: NA

Where it's running

• Centro Riferimento Oncologico CRO
  Aviano, Pordenone, Italy Recruiting
• AOU San Luigi Gonzaga
  Orbassano, Torino, Italy Recruiting
• Istituto Ortopedico Rizzoli IOR
  Bologna, Italy Recruiting
• Policlinico "Sant'Orsola-Malpighi"
  Bologna, Italy Recruiting
• Ospedale Policlinico san Martino IRCCS
  Genova, Italy Recruiting
• IRCCS Istituto Nazionale Tumori - Milano
  Milan, Italy Recruiting

Study contacts

• Principal investigator: Elena Palassini — IRCCS Istituto nazionale Tumori - Milano
• Study coordinator: Gianluca Ignazzi
• Email: gianluca.ignazzi@italiansarcomagroup.org
• Phone: +393335359192

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalised neoadjuvant therapy planning for adults with high‑risk soft tissue sarcoma

  This project tests whether analyzing tumor tissue and clinical data can help guide neoadjuvant chemotherapy decisions for adults with high‑risk soft tissue sarcomas.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT07432932

• VO plus pembrolizumab for angiosarcoma

  This study tests whether injecting Vusolimogene Oderparepvec (VO) into tumors, together with pembrolizumab, can help people with advanced angiosarcoma who have already tried other immunotherapies.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT06898970

• Combining immune therapy with chemotherapy for advanced soft tissue sarcoma

  This study is testing if combining a new immune therapy with standard chemotherapy can help people with advanced soft tissue sarcoma who can’t have surgery or radiation feel better and live longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06849986

• Evaluating AGX101 for advanced solid tumors

  This study is testing a new drug called AGX101 to see if it can help people with advanced solid tumors who haven't had success with other treatments.

  Recruiting at 7 sites Phase 1 Angiex, Inc. · Los Angeles, California and 6 other locations · NCT06440005

• MASCT-I plus doxorubicin and ifosfamide as first-line treatment for advanced soft tissue sarcoma

  This trial will test whether adding MASCT-I to standard chemotherapy (doxorubicin and ifosfamide) helps adults with advanced soft tissue sarcoma respond better or live longer.

  Recruiting Phase 2 HRYZ Biotech Co. · Guangzhou · NCT06277154

• Evaluating treatments for non-rhabdomyosarcoma soft tissue sarcoma in young patients

  This study is testing a combination of chemotherapy and radiation to see if it helps young patients with non-rhabdomyosarcoma soft tissue sarcoma live longer without their cancer coming back.

  Recruiting at 7 sites Phase 1/2 St. Jude Children's Research Hospital · Atlanta, Georgia and 6 other locations · NCT06239272

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.